[6] Zhou X, Yao Z, Bai H, et al. Treatment‐related adverse events of PD‐1 and PD‐L1 inhibitor‐based combination therapies in clinical trials: a systematic review and meta‐analysis[J]. Lancet Oncol, 2021, 22(...
A safe and potent CB1 inhibitor would have the potential to block the biological processes induced by supraphysiological CB1 activation and provide a novel treatment to patients. Learn More Pipeline We are building our innovative pipeline with the singular focus to advance peripherally acting CB1r bloc...
The goal of this clinical trial is to evaluate the safety and efficacy of nabiximols, a cannabinoid spray, for the treatment of moderate to severe spasticity in adult patients with AQP4-IgG positive and antibody-negative NMOSD. The main question it aims to answer is whether treatment with nabi...
The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011;179(2):880–9. Article CAS Google Scholar McKinnon BD, Kocbek V, Nirgianakis K, Bersinger NA, Mueller MD. Kinase signalling pathways in endometriosis: potential targets for non-hormonal ...
Transient transfection of hepatocytes with a miR-22 hairpin inhibitor reduced the ability of the cells to accumulate fat following exposure to O:P (L) or ACEA (M) treatment. ACEA was unable to reduce the expression of PPARα (N) and SIRT1 (O) in the transfected cells with a miR-22 ...
In these cells, rimonabant increased 2-deox- yglucose uptake, which was blunted by co-incubation with the PI3K inhibitor LY294002. In our experiments, we found that treatment with the PI3K inhibitor wortmannin had no effects on the inhibition of IL-6 induction by rimonabant, suggest- ing ...
Furthermore, rats treated with AM251 or MJN110–AM251 were significantly less active on the saline trial, but not the MWD trial, than rats that were treated with VEH or MJN110. DISCUSSION Systemic administration of the MAGL inhibitor, MJN110, prevented the establishment of a naloxone-...
These data demonstrate a biphasic and dose-sensitive role for the cannabinoid system in behavioral flexibility, which in turn may have clinical implications for the role of the endocannabinoid system in psychiatric disorders where behavioral flexibility is compromised....
These data demonstrate a biphasic and dose-sensitive role for the cannabinoid system in behavioral flexibility, which in turn may have clinical implications for the role of the endocannabinoid system in psychiatric disorders where behavioral flexibility is compromised. ...
Rother et al., “Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinura,” Nature Biotechnology, Nov. 2007, pp. 1256-1264, vol. 25, No. 11. Sensi et al., “Unique Tumor Antigens: Evidence for Immune Control of Genome Integrit...